Vir Biotechnology, Inc. (VIR) vs Zymeworks Inc. (ZYME)
Vir Biotechnology, Inc. and Zymeworks Inc. are both Biotechnology companies. Vir Biotechnology, Inc. and Zymeworks Inc. are of similar size ($1.9B and $1.8B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,495.9% against −69.8%. Vir Biotechnology, Inc. has the higher net margin (−83.0% vs −404.0%) and the lower return on invested capital (−39.1% vs 0.00%). Across the 17 metrics below, Vir Biotechnology, Inc. leads on 11 and Zymeworks Inc. on 6.
Valuation
Profitability
| Metric | VIR | ZYME | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | (246.66%) | 65.16% |
| Operating margin | (92.40%) | (418.99%) | 0.00% |
| Net margin | (83.00%) | (404.00%) | 0.00% |
| Free cash flow margin | (67.17%) | (324.68%) | 0.00% |
| Return on equity | (26.08%) | (72.31%) | (57.72%) |
| Return on assets | (20.91%) | (37.25%) | (49.22%) |
| Return on invested capital | (39.10%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack